IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:04 2024-04-26 am EDT			5-day change	1st Jan Change
8.625 ^GBX	0.00%		-1.43%	-31.00%

Apr. 15	Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	AN
Apr. 15	IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	CI

Ixico CEO Cerroni to retire by end of 2024; starts succession search

January 12, 2024 at 05:18 am EST

(Alliance News) - Ixico PLC on Friday said that Chief Executive Officer Giulio Cerroni will retire from his role by the end of 2024.

The London-based precision analytics company working to advance investigational therapies for neurological diseases said it started the process to appoint a new CEO, and will publish an update "in due course."

Ixico shares fell 3.1% to 12.60 pence each on Friday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Latest news about IXICO plc

Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	Apr. 15	AN
IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	Apr. 15	CI
Ixico inks collaboration with IMEKA Solutions	Apr. 03	AN
IXICO plc Announces Collaboration Agreement with IMEKA Solutions Inc. to Provide Access to Imeka's Suite of Services for White Matter Imaging deployed in Alzheimer's Disease and Multiple Sclerosis Clinical Trials, Amongst Other CNS Indications	Apr. 03	CI
Ixico shares fall 20% as revenue to decline, hit by delays to projects	Mar. 13	AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit	Mar. 13	AN
FTSE 100 slips but CAC and DAX hit record highs	Mar. 13	AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search	Jan. 12	AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024	Jan. 12	CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024	Jan. 12	CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023	Dec. 05
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit	Dec. 05	AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 05	CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees	23-10-05	CI
EARNINGS AND TRADING: Barkby revenue dips; Ixico hurt by trial delays	23-09-29	AN
IXICO plc Provides Earnings Guidance for the Full Year of 2023	23-09-29	CI
Andrada raises GBP7.7 million; Ixico signs contract	23-07-18	AN
IXICO plc Announces Contract Win for A Phase 3 Progressive Supranuclear Palsy Study	23-07-18	CI
IXICO Receives New GBP2 Million Imaging Services Contract	23-06-14	MT
Ixico wins Huntington's disease contract worth GBP2 million	23-06-14	AN
IXICO plc Announces Contract Win in Huntington's Disease	23-06-14	CI
Transcript : IXICO plc, H1 2023 Earnings Call, May 23, 2023	23-05-23
Ixico shares drop as firm swings to interim loss on cancelled trials	23-05-23	AN
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP3.2M	23-05-23	MT
Earnings Flash (IXI.L) IXICO Reports Fiscal H1 Loss GBX-1.50	23-05-23	MT

Chart IXICO plc

Duration

Period

More charts

Company Profile

IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for IXICO plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IXICO PLC	-31.00%	5.19M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research